Zenas BioPharma, Inc. (ZBIO) earnings

ZBIO earnings moved a median of -0.56% by the close. Quarterly and annual ZBIO reports and results, each read against the price at its own news timestamp. Back to the ZBIO overview →

16 measured ZBIO earnings events.

Where these ZBIO earnings landedvs 14 measured ZBIO earnings reactions
ZBIO earningsMiddle 50% · -3.49% to +1.68%Zero: 0.00%Median: -0.56%Median -0.56%-5.00%0+5.00%
Middle 50% of ZBIO earnings reactions-3.49% to +1.68%
Median reaction (to close)-0.56%
Measured reactions14
Point-in-time · zero look-ahead

Half of the 14 ZBIO earnings events with a measured close landed between -3.49% and +1.68%; 36% closed up.

DateHeadlineEvent5-minTo close
Form 10-Q Zenas BioPharma, Inc. For: Sep 30SEC filing · Form 10-Q-0.50%-7.72%
Zenas BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatePress release-0.50%-7.72%
Form 10-Q Zenas BioPharma, Inc. For: Jun 30SEC filing · Form 10-Q-2.76%-3.92%
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatePress release-2.76%-3.92%
Form 10-Q Zenas BioPharma, Inc. For: Mar 31SEC filing · Form 10-Q-0.66%+1.68%
Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate UpdatePress release-0.66%+1.68%
Form 10-K Zenas BioPharma, Inc. For: Dec 31SEC filing · Form 10-K-0.21%-0.51%
Form 10-Q Zenas BioPharma, Inc. For: Sep 30SEC filing · Form 10-Q-1.28%-0.56%
Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate UpdatePress release-1.28%-0.56%
Form 10-Q Zenas BioPharma, Inc. For: Jun 30SEC filing · Form 10-Q——
Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatesPress release——
Form 10-Q Zenas BioPharma, Inc. For: Mar 31SEC filing · Form 10-Q-0.11%+6.80%
Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesPress release-0.11%+6.80%
Form 10-K Zenas BioPharma, Inc. For: Dec 31SEC filing · Form 10-K+0.61%+6.62%
Form 10-Q Zenas BioPharma, Inc. For: Sep 30SEC filing · Form 10-Q—-1.73%
Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesPress release-0.28%-2.23%
That’s how ZBIO usually reacts to earnings — get an email when it moves on news →
Keep exploring

More ZBIO: analyst actions → · SEC filings → · ZBIO overview →